Breast Cancer

Lilly concludes lower dose of Alimta in metastatic breast cancer suitable for further study

Published in Women's Health Weekly, July 6th, 2006

Eli Lilly and Company announced results of a phase 2 trial evaluating its thoracic cancer drug Alimta (pemetrexed) in first-line metastatic breast cancer. The study also detailed exploratory pharmacogenomic analyses to potentially identify the presence of specific biomarkers for Alimta.

Lilly's study is among the first bodies of research evaluating the potential use of biomarkers with chemotherapy agents. Results were announced at the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Georgia.

The phase 2 study was a randomized, double-blind trial of 92 patients with locally advanced or metastatic breast cancer (MBC). The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2006-07-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry